Vermillion Downgraded by Canaccord to Hold Rating

May 24, 2018

|

NEW YORK (360Dx) – Following Vermillion's disappointing first quarter financial results, investment bank Canaccord Genuity today downgraded the company's shares to a Hold rating from a previous Buy rating.

Canaccord also cut its price target on Vermillion's shares to $1 from $2.25.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Vermillion Downgraded by Canaccord to Hold Rating

To read the full story....

Breaking News

BARDA Awards $5.4M to Luminex for Expanded Respiratory Panel With Coronavirus Target

In Brief This Week: Thermo Fisher Scientific, Fluidigm, Veracyte, and More

Exact Sciences Stock Soars on New Data Around Pan-Cancer Liquid Biopsy Test

BGI Genomics Gets CE Mark for Multiplexed SARS-CoV-2, Influenza Tests

Commercial Coronavirus Antibody Tests Show Wide Variation in Accuracy in New Study

Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

What's Popular?

Babson Diagnostics Raises $13.7M In Series A Financing

FDA Grants Emergency Use Authorizations for Quadrant Biosciences, KimForest Coronavirus Tests

Grail Deal Will Enable Illumina to Expand From Tech Innovator to Diagnostics Provider

Clear Labs Nanopore Sequencing Coronavirus Test Gets FDA Emergency Use Authorization

FDA Grants Emergency Use Authorization for GK Pharmaceuticals Coronavirus Test

Sponsorships